Segment Information (Details 2) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Financing Receivable, Past Due [Line Items]
Revenue	$ 10,651	$ 8,877
Other revenue	480	496
Interest expense	80	145
Manufacturing, research and development	1,901	1,548
Depreciation and amortization expense	704	1,682
General and administrative	3,160	2,885
Other income, net	(721)	1,215
Income tax expense	1,087	939
Net income (loss)	3,478	3,389
Financing Receivable [Member]
Financing Receivable, Past Due [Line Items]
Revenue	10,415	8,679
Other revenue
Interest expense	80	145
Manufacturing, research and development
Depreciation and amortization expense
General and administrative	102	184
Other income, net	(721)	1,215
Income tax expense
Net income (loss)	9,512	9,565
Pharmaceutical Development Services [Member]
Financing Receivable, Past Due [Line Items]
Revenue	236	198
Other revenue	480	496
Interest expense
Manufacturing, research and development	1,901	1,548
Depreciation and amortization expense	704	1,680
General and administrative	1,035	1,106
Other income, net
Income tax expense
Net income (loss)	(2,924)	(3,640)
Holding Company And Other [Member]
Financing Receivable, Past Due [Line Items]
Revenue
Other revenue
Interest expense
Manufacturing, research and development
Depreciation and amortization expense		2
General and administrative	2,023	1,595
Other income, net
Income tax expense	1,087	939
Net income (loss)	$ (3,110)	$ (2,536)